healthcare market

The report "Healthcare Fraud Analytics Market by Solution Type (Descriptive, Predictive, Prescriptive), Application (Insurance Claim (Postpayment, Prepayment), Payment Integrity), Delivery (On-premise, Cloud), End User (Insurance, Government) - Global Forecast to 2025", is projected to reach USD 4.6 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 29.8% during the forecast period. 

Don’t miss out on business opportunities in Healthcare Fraud Analytics Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=221837663 

“The prescriptive analytics segment registered the highest growth during the forecast period.” 
Fraud analytics solutions vary from vendor to vendor. Some vendors offer rule-based models while others offer AI-based technologies, but broadly, these solutions are classified based on the type of analytics used—descriptive analytics, predictive analytics, and prescriptive analytics. The prescriptive analytics segment registered the highest growth in the healthcare fraud analytics market during the forecast period. 

“In 2019, public & government agencies accounted for the largest share of the healthcare fraud analytics market, by end user.” 
Based on end user, the healthcare fraud detection market is segmented into public & government agencies, private insurance payers, employers, and third-party service providers. The public & government agencies segment accounted for the largest share of the healthcare fraud analytics market in 2019. 

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=221837663 

Key Players 
IBM Corporation (US), Optum (US), SAS Institute (US), Change Healthcare (US), EXL Service Holdings (US), Cotiviti (US), Wipro Limited (Wipro) (India), Conduent (US), HCL (India), Canadian Global Information Technology Group (Canada), DXC Technology Company (US), Northrop Grumman Corporation (US), LexisNexis Group (US), and Pondera Solutions (US). 

IBM is a leading player in the healthcare fraud detection market. The leading position of the company is attributed to its robust product portfolio. The company offers exhaustive healthcare fraud analytic solutions for application in healthcare. The company has a strong presence in the commercial and government healthcare payer markets. For instance, since 2005, the company has invested USD 24 billion in the development of its Big Data and Analytics software and services capabilities. For instance, in April 2016, IBM acquired Truven (US), a provider of cloud-based healthcare data, analytics, and insights. 

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=221837663

The report "Slide Stainer Market by Product (Reagent, Equipment (Automated, Manual)), Technology (Hematoxylin & Eosin, Immunohistochemistry, In Situ Hybridization, Microbiology, Special Stains), End User (Hospital, Pharmaceutical, Academic) - Global Forecast to 2023", The slide stainers market is expected to reach USD 4.70 billion by 2023 from an estimated USD 2.79 billion in 2018, at a CAGR of 11.0%. 

Don’t miss out on business opportunities in Slide Stainer Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=134046412 

“By product, the reagents segment accounted for the largest share of the slide stainers market in 2017” 
On the basis of product, the reagents segment accounted for the largest share of the global slide stainers market in 2017. The large share of this segment is attributed to the rising prevalence of chronic and infectious diseases, increasing healthcare expenditure, increasing public awareness, and growing demand for automation in diagnostics and clinical research. 

“By technology, the hematoxylin & eosin (H&E) segment held the largest share in 2017” 
Based on technology, the slide stainers market is segmented into hematoxylin and eosin (H&E), immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special stains. In 2017, the H&E segment accounted for the largest share of the slide stainers market. The large share of this segment can be attributed to the fact that H&E staining is the initial staining technique for various diseases and is associated with better quality, ease of use, and higher throughput than most other staining technologies. 

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134046412 

Key Players 
Roche (Switzerland), Agilent (US), Danaher (US), BioGenex (US), Thermo Fisher Scientific (US), Sakura (Japan), Biocare Medical (US), Merck Group (Germany), General Data Company (US), and Hardy Diagnostics (US). 

Roche (Switzerland) held the leading position in the global slide stainers market in 2017. The company has a diversified product portfolio, which includes a wide range of instruments, reagents, and accessories. The company’s leading position can be attributed to its strong distribution network across the globe, which enables it to serve customers in North America, Europe, Asia, the Middle East, Africa, and Latin America. The company focuses on growth strategies such as product launches, partnerships, and expansions to enhance its market share in the global slide stainers market. For instance, in 2018, the company partnered with GE Healthcare (UK) to jointly develop and co-market an integrated diagnostic platform to improve oncology and critical care treatment. 

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=134046412

The report "Dental 3D Printing Market by Product (Material (Plastic, Metal), Equipment (3D Printer, 3D Scanner), Service) Technology (Stereolithography, FDM, SLS, Polyjet) Application (Prosthodontics, Implantology, Orthodontic), End User - Global Forecast to 2023", The dental 3D printing market is expected to reach USD 5.06 billion by 2023 from an estimated USD 1.78 billion in 2018, at a CAGR of 23.2%. 

Don’t miss out on business opportunities in Dental 3D Printing Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=258228239 

“By technology, the vat photopolymerization segment accounted for the largest share of this market in 2017” 
On the basis of technology, this market is segmented into vat photopolymerization, fused deposition modeling, selective laser sintering, polyjet technology, and other technologies. The vat photopolymerization segment accounted for the largest share of the global dental 3D printing market. The high precision and accuracy of this technique is primarily attributed to the large share of this segment. 

“By application, the prosthodontics segment held the largest share of the dental 3D printing market in 2017” 
Based on application, this market is segmented into prosthodontics, endodontics, and implantology. The prosthodontics segment accounted for the largest share in this market. The large share of this segment can primarily be attributed to the growing demand for crowns and bridges, rising prevalence of dental caries, increasing incidence of tooth loss, and increasing customer acceptance of advanced dental technologies. 

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258228239 

Key Players 
3D Systems (US), Stratasys (US/Israel), Renishaw (UK), Roland DG (Japan), SLM Solutions (Germany), EnvisionTEC (Germany), DENTSPLY Sirona (US), Straumann (Switzerland), Formlabs (US), Prodways Group (France), EOS (Germany), Rapid Shape (Germany), DWS (Italy), Planmeca (Finland), Kulzer GmbH (Germany), Ultimaker (Netherlands), Dental Wings (Canada), Carbon (US), and Asiga (Australia). 

Stratasys (US & Israel) dominated the dental 3D printing market in 2017. The company’s 3D printing product portfolio includes a wide range of 3D printing systems and consumables through which it caters to the demand of various industries, including dentistry. The company also offers services associated with its 3D printing products. The company primarily focuses on product innovation and product launches as its key business strategy to sustain its leadership position in the global 3D printing market. For instance, the company launched its J700 Dental 3D Printing System in 2017. Additionally, in order to ensure its future growth, the company adopted strategies such as partnerships, agreements, mergers, and acquisitions to strengthen its product portfolio and customer base and expand its presence across various regions. 

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=258228239

The report "Cleanroom Technologies Market by Product (HVAC, HEPA filters, air shower, apparel, gloves, vacuum systems, disinfectants), Construction (Drywall, Hardwall, Softwall), End User (Pharmaceutical, Biotechnology, Hospitals) - Global Forecast to 2024" The cleanroom technologies market size is expected to reach USD 7.9 billion by 2024 from USD 5.7 billion in 2019, growing at a CAGR of 6.6%. 

Don’t miss out on business opportunities in Cleanroom Technology Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=263122482

"By product, the consumables segment is expected to account for the largest share of the cleanroom technologies market"
The consumables segment is estimated to account for the largest market share in 2018. The large share of this segment can be attributed to the high and growing number of pharmaceutical, biotech, and medical device companies facilitating the use of disposable protective clothing. Also, the large number of R&D activities in the healthcare industry is resulting in a stable demand for cleanroom consumables among end-users. This segment includes safety consumables and cleaning consumables.

"In the cleanroom construction market, by type, the hardwall cleanrooms segment is expected to grow at the highest CAGR during the forecast period"
The hardwall cleanrooms segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment can be attributed to factors such as the higher demand for hardwall cleanrooms, as they are more design-flexible than standard and softwall cleanrooms, quick and easy to install, freestanding for easy portability, and easy to expand or reconfigure.

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263122482

Key Players
Azbil Corporation (Japan), Kimberly-Clark Corporation (US), Ardmac (Ireland), Clean Air Products (US), Labconco Corporation (US), Dynarex Corporation (US), DowDuPont Inc. (US), Illinois Tool Works Inc. (US), Taikisha Ltd. (Japan), Exyte AG (Germany), COLANDIS GmbH (Germany), ABN Cleanroom Technology (Belgium), Clean Rooms International, Inc. (US), Bouygues Group (France), Terra Universal, Inc. (US), Connect 2 Cleanrooms Ltd (UK), Camfil (Sweden), OCTANORM-Vertriebs-GmbH (Germany), Parteco Srl (Italy), and Airtech Japan, Ltd. (Japan).

Kimberly-Clark has an extensive range of cleanroom consumables and a prominent presence across the globe. It targets faster-growing as well as higher-margin segments such as wiping & safety consumables within the K-C Professional business segment to achieve further growth.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=263122482

The report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services), Application (Cell Biology, Stem Cells, Drug Discovery), End User (Pharmaceutical & Biotechnology Companies, Research Institutes) - Global Forecasts to 2023", the live cell imaging market is expected to reach USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9% during the forecast period (2018–2023).

Don’t miss out on business opportunities in Surgical Drapes Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=163914483

The instruments segment accounted for the largest share of the market in 2018

On the basis of product and service, the global live cell imaging market is segmented into instruments, consumables, software, and services. In 2018, the instruments segment accounted for the largest share of the live cell imaging market. Factors such as the launch of new and advanced instruments, increasing incidence of diseases, and rising government initiatives and awareness programs for promoting cell-based research are the major factors driving the demand for live cell imaging instruments.

The academic & research institutes segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the live cell imaging market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations (CROs). The academic & research institutes segment is expected to grow at a higher CAGR during the forecast period. The high growth in this segment can be attributed to the increasing focusing of academic and research institutes on strengthening their own drug discovery research programs coupled with rising government funding to support research and advancing scientific goals.

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

Key Players

Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), and NanoEnTek Inc. (Korea) 

Danaher dominated the live cell imaging market in 2017. The company is a global leader in live cell imaging and has been operating in the market for about 50 years. Its innovative capabilities are evident from the products the company has launched in recent years, such as the SP8 FALCON launched in March 2018, which is an integrated contrast microscope that enables researchers to monitor interactions between proteins in living cells. R&D is a key area of focus for Danaher—it invested USD 1.13 billion in R&D activities in 2017. The company focuses on improving its R&D capabilities to unlock additional synergies and growth opportunities.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=163914483

The report "ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023", The ELISpot and FluoroSpot market is expected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2%.

Don’t miss out on business opportunities in Surgical Drapes Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=124350584

“Assay kits are projected to dominate the ELISpot and FluoroSpot market in 2018”
By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits are further subsegmented by utility, type, and analyte. In 2018, the assay kits segment is expected to account for the largest share of the market. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.

“Diagnostic applications to hold the largest share of the market in 2018”
Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications. In 2018, the diagnostic applications segment is expected to account for the larger share of the ELISpot and FluoroSpot market in 2018. The large share of this segment can be attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584

Key Players
Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), Abcam (UK), Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands).

Oxford Immunotec is the leading player in the ELISpot and FluoroSpot market. The company focuses on the development of diagnostic kits for the early detection of diseases such as TB and tick-borne diseases. The company has its presence across the globe and to maintain and improve its presence in the market; Oxford Immunotec adopted both organic as well as inorganic strategies. The company also invests a significant amount on research and development activities. In 2017, it spent around 16% of its revenue on R&D activities, which is higher than most of its counterparts.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=124350584

The report "Aspiration & Biopsy Needles Market by Product (Fine-needle Aspiration, Biopsy (Core & Vacuum Assisted)), Site, Procedure (Image-guided (Ultrasound, MRI, Stereotactic), Nonimage-guided), Enduser (Hospital, Academia) - Global Forecast to 2024", The aspiration and biopsy needles market is projected to reach USD 1,272 million by 2024 from USD 894 million in 2019 at a CAGR of 7.3%

Don’t miss out on business opportunities in Aspiration and Biopsy Needles Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=71036825

“Biopsy needles accounted for the largest share of the aspiration and biopsy needles market, by product, in 2018.”
On the basis of product, the aspiration and biopsy needles market is segmented into aspiration and biopsy needles. The biopsy needles segment accounted for the largest share of the aspiration and biopsy needles market in 2018 due to its widespread adoption in healthcare facilities. This segment is also expected to grow at the highest rate during the forecast period.

“The lung segment is expected to register the highest growth rate in the aspiration and biopsy needles market during the forecast period by site, in 2019”
On the basis of site, the aspiration and biopsy needles market is segmented into breast, lung, colorectal, prostate, kidney, and bone & bone marrow. The lung segment is expected to register the highest growth rate due to the increasing prevalence of lung cancer.

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71036825

Key Players
CONMED Corporation (US), Medtronic Plc (Ireland), Olympus (Japan), Becton, Dickinson and Company (US), Boston Scientific Corporation (US), Cook Group Incorporated (US), Argon Medical Devices, Inc (US), INRAD Inc. (US), Somatex Medical Technologies (Germany), Stryker Corporation (US), Cardinal Health (US), Remington Medical (US), HAKKO CO.,LTD (Japan), and Merit Medical Systems (US)

Becton, Dickinson and Company (US) is a leading player in the aspiration and biopsy needles market. The company offers a wide range of biopsy products, including breast biopsy, bone marrow biopsy, and soft tissue biopsy forceps and needles. With a strong presence in North America, Europe, and APAC, the company focuses on expanding its geographic presence in emerging countries with expanding healthcare systems in Eastern Europe, the Middle East, Africa, Latin America, and certain countries within APAC. For instance, in April 2017, the company acquired C. R. Bard, Inc. (US) for USD 24 billion. It also acquired CareFusion Corporation (US) in March 2015 and positioned itself as a major player in the aspiration and biopsy needle market. These acquisitions are expected to boost the company’s presence in the market.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=71036825

The report "Urinalysis Market by Product (Dipsticks, Pregnancy & Fertility Kits, Reagents, Disposables, Automated, Semi-automated, PoC Analyzers), Application (UTI, Diabetes, Pregnancy), End User (Hospital, Labs, Homecare) & Test Type - Global Forecast to 2024" The Global urinalysis market is projected to reach USD 4.6 billion by 2024 from USD 3.2 billion in 2019, at a CAGR of 7.6% from 2019 to 2024. 

Don’t miss out on business opportunities in Urinalysis Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153479294

Pregnancy and fertility tests to dominate the urinalysis market in 2019.
On the basis of test type, the urinalysis market is segmented into biochemical urinalysis, sediment urinalysis, and pregnancy & fertility tests. In 2019, pregnancy & fertility tests are expected to account for the largest market share. Growing use of these kits in home care settings is driving the growth of this segment.

Hospitals & clinics expected to dominate the urinalysis market in 2019.
By end user, the urinalysis market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, and research laboratories & institutes. In 2019, hospitals & clinics are expected to account for the largest share of 40% of the market. The large share of this segment can be attributed to factors such as the rapidly growing aging population, the increase in reimbursements for clinical tests performed in hospitals, and the launch of automated urinalysis devices

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153479294

Key Players
SeimensHealthineers (Germany), Roche Diagnostics (Switzerland), Cardinal Health (US), ArkrayInc (Japan), Sysmex Corporation (Japan), Alere Inc. (US), Beckman Coulter (US), Biorad Laboratories (US), 77 ElektronikaKft (Hungary), and DIRUI (China).

Siemens Healthineers is the leader in the biochemical urinalysis market. The company offers a robust product portfolio and has a strong geographic presence, which has helped it to maintain its position in the market. Siemens offers automatic and semi-automatic biochemical analyzers, as well as point of care devices and consumables, such as dipsticks. Some of the products offered by the company are CLINITEK Novus Automated Urine Chemistry Analyzers, CLINITEK Atlas Automated Urine Chemistry Analyzers (Carousel), CLINITEK AUWi Systems, and CLINITEK Advantus Urine Chemistry Analyzers. Siemens primarily focuses on developing new and innovative products to expand its product portfolio and address the unmet needs of healthcare providers. It launched the Atellica 1500 automated urinalysis system in 2017.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=153479294

The report "Animal/Veterinary Ultrasound Market by Type (2D, 3D/4D, Doppler), Technology, Product (Portable, Cart-based), Animal (Small Companion, Large), Application (Obstetrics, Orthopedics, Cardiology), End User, and Region - Global Forecast to 2025" The global animal/veterinary ultrasound market size is projected to reach USD 448 million by 2025 from USD 338 million in 2020, at a CAGR of 5.8%.

Don’t miss out on business opportunities in Veterinary Ultrasound Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=10482074

The 2D ultrasound segment dominates the animal/veterinary ultrasound industry, by type of ultrasound scanners  

Based on the type of scanners, the 2D segment accounted for the largest share of the animal/veterinary ultrasound market in 2019. The large share of this segment can primarily be attributed to the widespread popularity of this type in disease diagnosis as well as in pregnancy detection.

By animal, the small companion animals segment accounted for the largest market share in 2019

Based on animal, the animal/veterinary ultrasound market is segmented into small companion animals, large animals, and other animals. The companion animals segment accounted for the largest market share in 2019. This segment is also projected to register the highest CAGR during the forecast period. The growth in this segment can be attributed to the growing adoption of companion animals and growing willingness of companion animal owners to spend more on animal health.

 Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10482074

Key Players

GE Healthcare (US), Heska Corporation (US), Siemens AG (Germany), FUJIFILM Holdings Corporation (Japan), Esaote SpA (Italy), Mindray Medical International, Ltd. (China), Samsung Medison Co., Ltd.( Korea), Diagnostic Imaging Systems Inc. (US), IMV imaging (Scotland), Shenzhen Ricso Technology Co., Ltd. (China), DRAMIÑSKI S.A. (Poland), Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI), Clarius Mobile Health (US) and SonoScape Medical Corporation  (China).

GE Healthcare (US) dominated the global animal/veterinary ultrasound market in 2019. The company has a diversified ultrasound product portfolio. GE Healthcare’s position in the market is attributed to its active R&D activities and wide distribution footprint across the world. The company’s total R&D expenditure in 2018 was USD 4.9 billion. The company offers a wide variety of ultrasound scanners as compared to other players operating in the market.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=10482074

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).

What the Market Looks Like?

Predicted to grow at a CAGR of 14.3 % during the forecast period, the global Real World Evidence Solutions market is estimated to reach USD 1,348.1 million by the end of 2023.

“By component, the data sets segment accounted for the largest share of the real world evidence market in 2017.”

On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

“By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.”

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

 Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

Geographical growth scenario of Real World Evidence Solutions Market

North America accounted for the largest share of the real world evidence market in 2017, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.

Leading market players

The prominent players in the Real World Evidence Solutions market include IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991

The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies.

What the Market Looks Like?

Predicted to grow at a CAGR of 7.2% during the forecast period, the global Protein Engineering market is estimated to reach USD 2.9 billion by the end of 2024.

“Instruments segment to account for the largest share of the market, by product & service, in 2019”

Based on product & service, the market is segmented into instruments, consumables, and software & services. Instruments formed the largest product segment in this market owing to technological advancements and the high price of mass spectroscopy and crystallography instruments (as compared to consumables).

“Monoclonal antibodies segment accounted for the largest share of the protein engineering market, by protein type, in 2019”

Based on protein type, the market is segmented into monoclonal antibodies, insulin, erythropoietin, interferons, vaccines, colony-stimulating factors, growth hormones, coagulation factors, and other proteins. Monoclonal antibodies accounted for the largest share of the market in 2019. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=898

Geographical growth scenario of Protein Engineering Market

The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global market, closely followed by Europe. Factors such as the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research are responsible for the large share of the North American market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. 

Leading market players

The prominent players in the Protein Engineering market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=898

The growth of this market is primarily driven by the increasing incidence of target diseases and the subsequent growth in the number of surgical procedures, growing demand for minimally invasive surgeries, and technological advancements.

What the Market Looks Like?

Predicted to grow at a CAGR of 7.2% during the forecast period, the global Anastomosis Device market is estimated to reach USD 2.9 billion by the end of 2024.

“By type, the surgical staplers segment accounted for the largest share of the market in 2018.”

Based on type, the anastomosis devices market is segmented into surgical staplers, surgical sutures, and surgical sealants & adhesives. Of all these segments, surgical staplers accounted for the largest share of the anastomosis devices market in 2018.

“By application, the gastrointestinal surgeries segment dominated the market in 2018.”

Based on application, the market is segmented into gastrointestinal surgeries, cardiovascular & thoracic surgeries, and other applications. Gastrointestinal surgeries accounted for the largest share of the anastomosis devices market in 2018. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=5343963

Geographical growth scenario of Anastomosis Device Market

In 2018, North America accounted for the largest share of the anastomosis devices market, followed by Europe. Factors such as the presence of advanced healthcare infrastructure in the region, increasing incidence of target diseases, growth in the number of cancer cases, increasing number of organ transplants, and the implementation of a new funding model for Canadian hospitals are contributing to the large share of North America.

Leading market players

The prominent players in the Anastomosis Device market include Johnson & Johnson (US), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), Smith & Nephew (UK), EndoEvolution LLC (US), CryoLife, Inc. (US), Becton, Dickinson and Company (US), CONMED Corporation (US), Intuitive Surgical, Inc. (US), Boston Scientific Corporation (US), Baxter International, Inc. (US), Péters Surgical (France), Biosintex (Romania), and Meril Life Sciences (India).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=5343963

The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis across the globe. Factors such as the growing number of surgical procedures, influx of novel sepsis diagnostic products, high incidence of hospital-acquired infections, funding for sepsis-related research activities, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market. 

What the Market Looks Like? 
Predicted to grow at a CAGR of 9.1% during the forecast period, the global Sepsis Diagnostics market is estimated to reach USD 869.7 million by the end of 2027. 

“Based on technology, the biomarkers segment is expected to register the highest growth rate during the forecast period” 
Based on technology, the global sepsis diagnostics market is segmented into— microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers. The biomarkers segment is expected to grow at the highest CAGR during the forecast period. 

“Based on product, the blood culture media segment accounted for the largest share of the market in 2018” 
On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. In 2018, the blood culture media segment accounted for the largest share of the market owing to the increased use of blood culture media as it is the standard method for diagnosis of sepsis across the globe. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155 

Geographical growth scenario of Sepsis Diagnostics Market 
Geographically, the sepsis diagnostic market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is expected register highest growth during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research. 

Leading market players 
The prominent players in the Sepsis Diagnostics market include bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany), among others. 

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155

The growth in this market is driven mainly by the increasing geriatric population and subsequent growth in the incidence of various diseases, advantages associated with specialty PACS, government initiatives to increase the adoption of healthcare IT solutions, increasing investments in medical imaging, growing adoption of medical imaging IT solutions, and increasing use of imaging equipment. 

What the Market Looks Like? 
Predicted to grow at a CAGR of 11.2% during the forecast period, the global Speciality PACS market is estimated to reach USD 2.2 billion by the end of 2024. 

“The Ophthalmology PACS segment is projected to grow at the highest CAGR during the forecast period.” 
Based on the type, the specialty PACS market is segmented into radiology PACS, cardiology PACS, pathology PACS, ophthalmology PACS, orthopedics PACS, oncology PACS, dermatology PACS, neurology PACS, endoscopy PACS, women’s health PACS, and other specialty PACS. The ophthalmology PACS segment is expected to register the highest CAGR of during the forecast period. 

“Based on the component, the services segment is projected to grow at the highest CAGR during the forecast period.” 
Based on the component, the specialty PACS market is segmented into software, services, and hardware. In 2018, the software segment accounted for the largest specialty PACS market share. With the consistent increase in the healthcare imaging volumes, there is a growing demand for PACS software. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66166054 

Geographical growth scenario of Speciality PACS Market 
In 2018, North America commanded the largest share of the market. The large share of this regional segment can be attributed to factors such as increasing medical imaging volumes and the number of diagnostic imaging centers, growing geriatric population, and the fast adoption of technologically advanced imaging systems. 

Leading market players 
The prominent players in the Speciality PACS market include IBM Corporation (Merge Healthcare Incorporated) (US), McKesson Corporation (US), Agfa Healthcare (Belgium), Carestream Health (a part of Onex Corporation) (Canada), Philips Healthcare (Netherlands), Sectra AB (Sweden), Siemens Healthineers (Germany), Novarad (US), INFINITT North America (US), Intelerad Medical Systems (Canada), Topcon Corporation (Japan), Sonomed Escalon (US), Canon USA, Inc. (US) (a subsidiary of Canon Inc.), Visbion (UK), and EyePACS, LLC (US). 

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=66166054

Growth in this market is driven by the increasing number of surgical procedures, growing number of regulatory approvals, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries.

What the Market Looks Like?

Predicted to grow at a CAGR of 6.0% during the forecast period, the global Hemostats market is estimated to reach USD 3.03 billion by the end of 2023.

“The thrombin-based hemostats segment is expected to account for the largest share of the market in 2018.”

Based on product, the hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Of all these product segments, the thrombin-based hemostats segment is expected to account for the largest share of the global hemostats market in 2018.

“In 2018, the orthopedic surgery segment is expected to dominate the hemostats market”

On the basis of application, the hemostats market is segmented neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries. The orthopedic surgery segment is expected to account for the largest share of the hemostats market in 2018.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619

Geographical growth scenario of Hemostats Market

On the basis of region, the hemostats market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America is expected to account for the largest share of the global hemostats market. The hemostats market in North America is well-established, with the US being a major market in this region. 

Leading market players

The prominent players in the Hemostats market include CR Bard, Inc. (US), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US), Integra LifeSciences (US), Marine Polymer Technologies, Inc. (US), Teleflex (US), Ethicon, Inc. (US), Pfizer, Inc. (US), Z-Medica LLC (US), and Gelita Medical GmbH (Germany).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=9571619

The major factors driving the CRISPR technology market include the rising funding from government and private organizations and the high adoption of CRISPR technology.

What the Market Looks Like?

Predicted to grow at a CAGR of 25% during the forecast period, the global CRISPR Technology market is estimated to reach USD 1,715 million by the end of 2023.

“The CRISPR products segment is expected to command the largest share of the CRISPR technology market during the forecast period.”

The CRISPR technology market, by product and service, is estimated to be dominated by the products segment in 2018. This is attributed to the fact that the CRISPR technology is being adopted quickly by academics and researchers, pharma and biotech companies.

“Biomedical applications to occupy the majority of the market, by application, and grow at the fastest rate during the forecast period.”

The biomedical applications segment is projected to be the fastest-growing segment of the market, by application, during the forecast period. Developments in gene therapy, drug discovery, and diagnostics, due to the application of CRISPR, are driving the growth of this biomedical segment.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204

Geographical growth scenario of CRISPR Technology Market

North America is estimated to account for the largest share of the market in 2018. The large share of CRISPR technology in this region is majorly attributed to the rising government and private funding, presence of major pharma and gene therapy companies, and the adoption of CRISPR in a number of applications.

Leading market players

The prominent players in the CRISPR Technology market include Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=134401204